BOSTON, March 10, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. TNGXa clinical-stage biotechnology company dedicated to discovering and delivering the next generation of precision cancer medicines, reported that it is aware of the current situation at Silicon Valley Bank (SVB), is closely monitoring this situation and does not expect to be exposed Any change to its previously provided guidance will require SVB to have sufficient cash and marketable securities to fund operations through 2025.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicines for the treatment of cancer. With an approach that begins and ends with patients, Tango uses the genetic principle of synthetic lethality to discover and develop therapies that target critical cancer targets. This includes expanding the universe of precision oncology targets into new areas such as the loss of tumor suppressor genes and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.

Forward-Looking Statements

Certain statements in this press release may be deemed to be forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future operating performance and goals, the anticipated benefits of therapies and combination therapies (including any Tango pipeline product), expectations, beliefs and development goals for Tango’s product pipeline and clinical trials. In some cases, you can identify forward-looking statements by words such as “may”, “should”, “expect”, “intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”. , “anticipate”, “designed”, “potential” or “continue” or the negative of these terms or variations thereof or similar terminology. For example, statements of the following include or constitute…